PT - JOURNAL ARTICLE AU - MCB, Gonçalves AU - T, Khera AU - HH, Otu AU - S, Narayanan AU - ST, Dillon AU - A, Shanker AU - X, Gu AU - Y, Jung AU - LH, Ngo AU - ER, Marcantonio AU - TA, Libermann AU - B, Subramaniam TI - Multivariable models of postoperative delirium in cardiac surgery patients: proteomic and demographic contributions AID - 10.1101/2023.05.30.23289741 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.30.23289741 4099 - http://medrxiv.org/content/early/2023/06/05/2023.05.30.23289741.short 4100 - http://medrxiv.org/content/early/2023/06/05/2023.05.30.23289741.full AB - Background: Delirium following cardiac surgery is common, morbid, and costly, but may be prevented with risk stratification and targeted intervention. Preoperative protein signatures may identify patients at increased risk for worse postoperative outcomes, including delirium. In this study, we aimed to identify plasma protein biomarkers and develop a predictive model for postoperative delirium in older patients undergoing cardiac surgery, while also uncovering possible pathophysiological mechanisms. Methods: SOMAscan analysis of 1,305 proteins in the plasma from 57 older adults undergoing cardiac surgery requiring cardiopulmonary bypass was conducted to define delirium-specific protein signatures at baseline (PREOP) and postoperative day 2 (POD2). Selected proteins were validated in 115 patients using the ELLA multiplex immunoassay platform. Proteins were combined with clinical and demographic variables to build multivariable models that estimate the risk of postoperative delirium and bring light to the underlying pathophysiology. Results: A total of 666 proteins from SOMAscan analysis were found altered between PREOP and POD2 (Benjamini-Hochberg (BH)-p<0.01). Using these results and findings from other studies, 12 biomarker candidates (Tukey’s fold change (|tFC|)>1.4) were selected for ELLA multiplex validation. Eight proteins were significantly altered at PREOP, and seven proteins at POD2 (p<0.05), in patients who developed postoperative delirium compared to non-delirious patients. Statistical analyses of model fit resulted in selecting a combination of age, sex, and different 3-protein biomarker panels highly correlated with delirium at PREOP (angiopoietin-2, ANGPT2; C-C motif chemokine 5, CCL5; and metalloproteinase inhibitor 1, TIMP1; AUC=0.829) and POD2 (lipocalin-2, LCN2; neurofilament light chain, NFL; and CCL5; AUC=0.845). The delirium-associated proteins identified as biomarker candidates are involved with inflammation, glial dysfunction, vascularization, and hemostasis, highlighting the multifactorial pathophysiology of delirium. Conclusion: Our study proposes two models of postoperative delirium that include a combination of older age, female sex, and altered levels of proteins both preoperatively and postoperatively. Our results support the identification of patients at higher risk of developing postoperative delirium after cardiac surgery and provide insights on the underlying pathophysiology. ClinicalTrials.gov (NCT02546765).CLINICAL PERSPECTIVESComprehensive proteomics screening of patients undergoing cardiac surgery and its association with the development of postoperative delirium.We propose two different multivariable models: the first model inputs information on risk factors for developing postoperative delirium after cardiac surgery, which could be used clinically to preoperatively predict those patients at higher risk; and the second model informs on postoperative proteomic signatures that bring light to delirium pathophysiology and underlying mechanisms for further investigation.Competing Interest StatementDr Subramaniam, and Dr Marcantonio reported receiving grant support from Mallinckrodt Pharmaceuticals during the conduct of the DexAcet trial. Drs. Subramaniam and Marcantonio are currently funded by NIH-R01AG065554. Dr. Marcantonio and Dr Libermann are funded by NIH R01-AG051658 and P01-AG031720. Dr. Marcantonio is also funded by NIH K24-AG035075. Mallinckrodt Pharmaceuticals had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The authors had sole authority for the data, analysis, write-up, and submission.Clinical TrialNCT02546765Funding StatementThe study was funded in part by Mallinckrodt Pharmaceuticals to conduct the SOMAscan analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Committee on Clinical Investigations - Institutional Review Board of Beth Israel Deaconess Medical Center (BIDMC; Boston, MA) gave ethical approval for this work. (CCI-IRB Protocol # 2019 P00075).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.